{
    "ticker": "CYTHW",
    "name": "CytoDyn Inc.",
    "description": "CytoDyn Inc. is a biotechnology company focused on the development of innovative therapies for the treatment of human immunodeficiency virus (HIV) and other serious diseases. Founded in 2005 and headquartered in Vancouver, Washington, CytoDyn is primarily known for its lead drug candidate, leronlimab (PRO 140), a monoclonal antibody that targets the CCR5 receptor, which plays a critical role in HIV infection. The company aims to provide new treatment options that improve the quality of life for patients living with HIV and potentially other conditions such as cancer and autoimmune disorders. CytoDyn is committed to advancing the science of immunology and addressing unmet medical needs through rigorous clinical trials and research. The company is also exploring leronlimab's potential applications in various therapeutic areas, including coronavirus infections, wherein it has shown promise in clinical studies. CytoDyn's mission is to make a meaningful difference in the lives of patients by delivering groundbreaking therapies that can lead to better health outcomes and improved patient care.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Vancouver, Washington, USA",
    "founded": "2005",
    "website": "https://www.cytodyn.com",
    "ceo": "Nader Pourhassan",
    "social_media": {
        "twitter": "https://twitter.com/CytoDyn",
        "linkedin": "https://www.linkedin.com/company/cytodyn-inc-"
    },
    "investor_relations": "https://www.cytodyn.com/investors",
    "key_executives": [
        {
            "name": "Nader Pourhassan",
            "position": "CEO"
        },
        {
            "name": "Scott Kelly",
            "position": "Chief Medical Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Leronlimab (PRO 140)"
            ]
        }
    ],
    "seo": {
        "meta_title": "CytoDyn Inc. | Innovative Therapeutics for HIV and More",
        "meta_description": "Learn about CytoDyn Inc., a biotechnology company developing innovative therapies for HIV and other serious diseases. Explore their lead drug candidate, leronlimab.",
        "keywords": [
            "CytoDyn",
            "HIV Treatment",
            "Leronlimab",
            "Biotechnology",
            "Pharmaceuticals",
            "Immunology"
        ]
    },
    "faq": [
        {
            "question": "What is CytoDyn known for?",
            "answer": "CytoDyn is known for developing innovative therapies for HIV and other serious diseases, particularly its lead drug candidate, leronlimab."
        },
        {
            "question": "Who is the CEO of CytoDyn?",
            "answer": "Nader Pourhassan is the CEO of CytoDyn Inc."
        },
        {
            "question": "Where is CytoDyn headquartered?",
            "answer": "CytoDyn is headquartered in Vancouver, Washington, USA."
        },
        {
            "question": "What is leronlimab?",
            "answer": "Leronlimab is a monoclonal antibody that targets the CCR5 receptor and is being developed for the treatment of HIV and other conditions."
        },
        {
            "question": "When was CytoDyn founded?",
            "answer": "CytoDyn was founded in 2005."
        }
    ],
    "competitors": [
        "GILD",
        "BMY",
        "VRTX"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "JNJ",
        "MRNA"
    ]
}